A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies

References

• Lindblad R, Rodjer S, Adriansson M, Andreasson B, Backstrom B, Johansson P, et al. Empirical monotherapy for febrile neutropenia: a randomized study comparing meropenem with ceftazidime. Scand J Infect Dis 1998; 30: 237–43.
   PubMed Web of Science ®Google Scholar
• Bohme A, Just-Nubling G, Bergmann L, Shah PM, Stille W, Hoelzer D. A randomized study of imipenem compared to cefotaxime plus piperacillin as initial therapy of infections in granulocytopenic patients. Infection 1995; 23: 349–55.
   PubMed Web of Science ®Google Scholar
• Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto Infection Program. Antimicrob Agents Che-mother 1996; 40: 1108–15.
   Google Scholar
• Deaney NB, Tate H. A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients. J Antimicrob Chemother 1996; 37: 975–86.
   PubMed Web of Science ®Google Scholar
• Fainstein V, Bodey GP, Elting L, Bolivar R, Keating MJ, McCredie KB, et al. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother 1983; 12(Suppl A): 101–10.
   Google Scholar
• Freifeld AG, Walsh T, Marshall D, Gress J, Steinberg SM, Hathorn J, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13: 165–76.
   PubMed Web of Science ®Google Scholar
• Hathorn JW, Pizzo PA. Is there a role for monotherapy with betalactam antibiotics in the initial empirical management of febrile neutropenic cancer patients? J Antimicrob Chemother 1986; 17(Suppl A): 41–54.
   Google Scholar
• Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730–51.
   Web of Science ®Google Scholar
• Kanellakopoulou K, Giamarellou H, Papadothomakos P, Tsipras H, Chloroyiannis J, Theakou R, et al. Meropenem vs imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 1993; 12: 449–53.
   PubMed Web of Science ®Google Scholar
• Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 1996; 100: S83–9.
   Google Scholar
• Rolston KV, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, et al. A comparison of imipenem to ceftazidime with or without amikacin as empirical therapy in febrile neutropenic patients. Arch Intern Med 1992; 152: 283–91.
   PubMed Web of Science ®Google Scholar
• Bohme A, Shah PM, Stille W, Hoelzer D. Antibiotic therapy in leukopenia. Schweiz Rundsch Med Prax 1998; 87: 1120–5.
   Google Scholar
• Bohme A, Shah PM, Stille W, Hoelzer D. Prospective randomized study to compare imipenem 1.5 g per d vs 3.0 g per d in infections of granulocytopenic patients. J Infect 1998; 36: 35–42.
   Google Scholar
• Piccart M, Klastersky J, Meunier F, Lagast H, van Laethem Y, Weerts D. Single-drug versus combination empirical therapy for Gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Che–mother 1984; 26: 870–5.
   PubMed Web of Science ®Google Scholar
• Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552–8.
   PubMed Web of Science ®Google Scholar
• Tamura K, Matsuoka H, Tsukada J, Masuda M, Ikeda S, Matsuishi E, et al. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of fourth-generation cephalosporin + aminoglycosides: comparative study. Am J Hematol 2002; 71: 248–55.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Lopez J, Lahuerta JJ, Rovira M, Batlle M, Perez C, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother 2002; 50: 79–88.
   PubMed Web of Science ®Google Scholar
• Bohme A, Shah PM, Stille W, Hoelzer D. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res 1998; 3: 324–30.
   PubMedGoogle Scholar
• Borbolla JR, Lopez-Hernandez MA, Gonzalez-Avante M, DeDiego J, Trueba E, Alvarado ML, Jimenez RM. Comparison of cefepime versus ceftriaxone-amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukemia patients. Chemotherapy 2001; 47: 381–4.
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Arnow PM. Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer. Ann Pharmacother 2000; 34: 989–95.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Herbrecht R, Pico JL, Gardembas M, Delmer A, Delain M, et al. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. Clin Infect Dis 1997; 24: 41–51.
   PubMed Web of Science ®Google Scholar
• Erman M, Akova M, Akan H, Korten V, Ferhanoglu B, Koksal I, et al. Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicentre study. Scand J Infect Dis 2001; 33: 827–31.
   PubMed Web of Science ®Google Scholar
• Gentry LO, Rodriguez-Gomez G. Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects. Antimicrob Agents Chemother 1991; 35: 2371–4.
   PubMedGoogle Scholar
• Mustafa MM, Carlson L, Tkaczewski I, McCracken GH Jr, Buchanan GR. Comparative study of cefepime versus ceftazidime in the empirical treatment of paediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 2001; 20: 362–9.
   Google Scholar
• Schaad UB, Eskola J, Kafetzis D, Fishbach M, Ashkenazi S, Syriopoulou V, et al. Cefepine versus ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 paediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. Pediatr Infect Dis J 1998; 17: 639–44.
   Google Scholar
• Wynd MA, Paladino JA. Cefepime: a fourth-generation parenteral cephalosporin. Ann Pharmacother 1996; 30: 1414–24.
   PubMed Web of Science ®Google Scholar
• Yee YC, Thornsberry C, Brown SD, Bouchillon SK, Marler JK, Rich T. A comparative study of the in vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 1993; 32(Suppl B): 13–9.
   Google Scholar
• Lewis MT, Yamaguchi K, Biedenbach DJ, Jones RN. In vitro evaluation of cefepime and other broad-spectrum beta-lactams in 22 medical centres in Japan: a phase II trial comparing 2 annual organism samples. The Japan Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1999; 35: 307–15.
   PubMedGoogle Scholar
• Sidorenko SV, Strachunskii LS, Akhmedova LI, Beloborodov VB, Bogomolova NS, Bol’shakov LV, et al. The results of a multicentre study of the comparative activity of cefepime and other antibiotics against the causative agents of severe hospital infections (the Micromax program). Antibiot Khimioter 1999; 44: 7–16.
   Google Scholar
• Raad II, Escalante C, Hachem RY, Hanna HA, Husni R, Afif C, et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 2003; 98: 1039–47.
   PubMed Web of Science ®Google Scholar
• Biron P, Fuhrmann C, Cure H, Viens P, Lefebvre D, Thyss A, et al. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). J Antimicrob Chemother 1998; 42: 511–8.
   Google Scholar
• Kaplan AH, Weber DJ, Davis L, Israel F, Wells RJ. Short courses of antibiotics in selected febrile neutropenic patients. Am J Med Sci 1991; 302: 353–4.
   Google Scholar
• Cohen KJ, Leamer K, Odom L, Greffe B, Stork L. Cessation of antibiotics regardless of ANC is safe in children with febrile neutropenia. A preliminary prospective trial. J Pediatr Hematol Oncol 1995; 17: 325–30.
   Google Scholar
• Jones GR, Konsler GK, Dunaway RP, Gold SH, Cooper HA, Wells RJ. Risk factors for recurrent fever after the discontinuation of empirical antibiotic therapy for fever and neutropenia in paediatric patients with a malignancy or haematological condition. J Pediatr 1994; 124: 703–8.
   PubMedGoogle Scholar
• From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis 1990; 161: 397–401.
   PubMedGoogle Scholar
• Andremont A, Lancar R, An Le N, Hattchouel JM, Baron S, Tavakoli T, et al. Secular trends in mortality associated with bloodstream infections in 4268 patients hospitalized in a cancer referral centre between 1975 and 1989. Clin Microbiol Infect 1996; 1: 160–7.
   PubMedGoogle Scholar
• Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteraemia in patients with cancer and neutropenia: observations from 2 decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25: 247–59.
   PubMed Web of Science ®Google Scholar
• Engervall P, Bjorkholm M. Infections in neutropenic patients. I: Aetiology Med Oncol 1995; 12: 251–6.
   PubMedGoogle Scholar
• Gunther G, Bjorkholm M, Bjorklind A, Engervall P, Stiernstedt G. Septicaemia in patients with haematological disorders and neutropenia. A retrospective study of causative agents and their resistance profile. Scand J Infect Dis 1991; 23: 589–98.
   Google Scholar
• Mortensen N, Mortensen BT, Nissen NI. Bacteraemia in patients with leukaemia and allied neoplastic diseases. Scand J Infect Dis 1976; 8: 145–9.
   PubMedGoogle Scholar
• Eggimann P, Glauser MP, Aoun M, Meunier F, Calandra T. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. J Antimicrob Chemother 1993; 32(Suppl B): 151–63.
   Google Scholar
• Engervall PA, Stiernstedt GT, Gunther GC, Bjorkholm MJ. Trimethoprim-sulfamethoxazole plus amikacin as first-line therapy and imipenem/cilastatin as second empirical therapy in febrile neutropenic patients with haematological disorders. J Chemother 1992; 4: 99–106.
   PubMed Web of Science ®Google Scholar
• Engervall P, Kalin M, Dornbusch K, Bjorkholm M. Cefepime as empirical monotherapy in febrile patients with haematological malignancies and neutropenia: a randomized, single-centre phase II trial. J Chemother 1999; 11: 278–86.
   PubMed Web of Science ®Google Scholar
• Fleming DR, Ziegler C, Baize T, Mudd L, Goldsmith GH, Herzig RH. Cefepime versus ticarcillin and clavulanate potassium and aztreonam for febrile neutropenia therapy in highdose chemotherapy patients. Am J Clin Oncol 2003; 26: 285–8.
   PubMed Web of Science ®Google Scholar
• Jandula BM, Martino R, Gurgi M, Manteiga R, Sierra J. Treatment of febrile neutropenia with cefepime monotherapy. Chemotherapy 2001; 47: 226–31.
   Google Scholar
• Lehrnbecher T, Stanescu A, Kuhl J. Short courses of intravenous empirical antibiotic treatment in selected febrile neutropenic children with cancer. Infection 2002; 30: 17–21.
   Google Scholar
• Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038–51.
   PubMed Web of Science ®Google Scholar
• Link H, Bohme A, Cornely OA, Hoffken K, Kellner O, Kern WV, et al. Antimicrobial therapy of unexplained fever in neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever. (DKG-German Cancer Society). Ann Hematol 2003; 82(Suppl 2): S105–17.
   Google Scholar